Promoting adoption of the 3Rs through regulatory qualification

Elizabeth Gribble Walker, Amanda F Baker, John Michael Sauer

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

One mechanism to advance the application of novel safety assessment methodologies in drug development, including in silico or in vitro approaches that reduce the use of animals in toxicology studies, is regulatory qualification. Regulatory qualification, a formal process defined at the the U. S. Food and Drug Administration and the European Medicines Agency, hinges on a central concept of stating an appropriate "context of use" for a novel drug development tool (DDT) that precisely defines how that DDT can be used to support decision making in a regulated drug development setting. When accumulating the data to support a particular "context-of-use," the concept of "fit-for-purpose" often guides assay validation, as well as the type and amount of data or evidence required to evaluate the tool. This paper will review pathways for regulatory acceptance of novel DDTs and discuss examples of safety projects considered for regulatory qualification. Key concepts to be considered when defining the evidence required to formally adopt and potentially replace animal-intensive traditional safety assessment methods using qualified DDTs are proposed. Presently, the use of qualified translational kidney safety biomarkers can refine and reduce the total numbers of animals used in drug development. We propose that the same conceptual regulatory framework will be appropriate to assess readiness of new technologies that may eventually replace whole animal models.

Original languageEnglish (US)
Pages (from-to)221-225
Number of pages5
JournalILAR Journal
Volume57
Issue number2
DOIs
StatePublished - 2016

Fingerprint

Animals
drugs
Safety
DDT
Pharmaceutical Preparations
safety assessment
animals
toxicology
Biomarkers
United States Food and Drug Administration
Hinges
Computer Simulation
Toxicology
Medicine
decision making
Assays
biomarkers
Decision Making
medicine
Animal Models

Keywords

  • Drug development tools
  • Regulatory qualification
  • Safety biomarkers

ASJC Scopus subject areas

  • Animal Science and Zoology
  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Promoting adoption of the 3Rs through regulatory qualification. / Walker, Elizabeth Gribble; Baker, Amanda F; Sauer, John Michael.

In: ILAR Journal, Vol. 57, No. 2, 2016, p. 221-225.

Research output: Contribution to journalArticle

Walker, Elizabeth Gribble ; Baker, Amanda F ; Sauer, John Michael. / Promoting adoption of the 3Rs through regulatory qualification. In: ILAR Journal. 2016 ; Vol. 57, No. 2. pp. 221-225.
@article{129e487c84664baca6f39169157e2027,
title = "Promoting adoption of the 3Rs through regulatory qualification",
abstract = "One mechanism to advance the application of novel safety assessment methodologies in drug development, including in silico or in vitro approaches that reduce the use of animals in toxicology studies, is regulatory qualification. Regulatory qualification, a formal process defined at the the U. S. Food and Drug Administration and the European Medicines Agency, hinges on a central concept of stating an appropriate {"}context of use{"} for a novel drug development tool (DDT) that precisely defines how that DDT can be used to support decision making in a regulated drug development setting. When accumulating the data to support a particular {"}context-of-use,{"} the concept of {"}fit-for-purpose{"} often guides assay validation, as well as the type and amount of data or evidence required to evaluate the tool. This paper will review pathways for regulatory acceptance of novel DDTs and discuss examples of safety projects considered for regulatory qualification. Key concepts to be considered when defining the evidence required to formally adopt and potentially replace animal-intensive traditional safety assessment methods using qualified DDTs are proposed. Presently, the use of qualified translational kidney safety biomarkers can refine and reduce the total numbers of animals used in drug development. We propose that the same conceptual regulatory framework will be appropriate to assess readiness of new technologies that may eventually replace whole animal models.",
keywords = "Drug development tools, Regulatory qualification, Safety biomarkers",
author = "Walker, {Elizabeth Gribble} and Baker, {Amanda F} and Sauer, {John Michael}",
year = "2016",
doi = "10.1093/ilar/ilw032",
language = "English (US)",
volume = "57",
pages = "221--225",
journal = "ILAR Journal",
issn = "1084-2020",
publisher = "Institute for Laboratory Animal Research",
number = "2",

}

TY - JOUR

T1 - Promoting adoption of the 3Rs through regulatory qualification

AU - Walker, Elizabeth Gribble

AU - Baker, Amanda F

AU - Sauer, John Michael

PY - 2016

Y1 - 2016

N2 - One mechanism to advance the application of novel safety assessment methodologies in drug development, including in silico or in vitro approaches that reduce the use of animals in toxicology studies, is regulatory qualification. Regulatory qualification, a formal process defined at the the U. S. Food and Drug Administration and the European Medicines Agency, hinges on a central concept of stating an appropriate "context of use" for a novel drug development tool (DDT) that precisely defines how that DDT can be used to support decision making in a regulated drug development setting. When accumulating the data to support a particular "context-of-use," the concept of "fit-for-purpose" often guides assay validation, as well as the type and amount of data or evidence required to evaluate the tool. This paper will review pathways for regulatory acceptance of novel DDTs and discuss examples of safety projects considered for regulatory qualification. Key concepts to be considered when defining the evidence required to formally adopt and potentially replace animal-intensive traditional safety assessment methods using qualified DDTs are proposed. Presently, the use of qualified translational kidney safety biomarkers can refine and reduce the total numbers of animals used in drug development. We propose that the same conceptual regulatory framework will be appropriate to assess readiness of new technologies that may eventually replace whole animal models.

AB - One mechanism to advance the application of novel safety assessment methodologies in drug development, including in silico or in vitro approaches that reduce the use of animals in toxicology studies, is regulatory qualification. Regulatory qualification, a formal process defined at the the U. S. Food and Drug Administration and the European Medicines Agency, hinges on a central concept of stating an appropriate "context of use" for a novel drug development tool (DDT) that precisely defines how that DDT can be used to support decision making in a regulated drug development setting. When accumulating the data to support a particular "context-of-use," the concept of "fit-for-purpose" often guides assay validation, as well as the type and amount of data or evidence required to evaluate the tool. This paper will review pathways for regulatory acceptance of novel DDTs and discuss examples of safety projects considered for regulatory qualification. Key concepts to be considered when defining the evidence required to formally adopt and potentially replace animal-intensive traditional safety assessment methods using qualified DDTs are proposed. Presently, the use of qualified translational kidney safety biomarkers can refine and reduce the total numbers of animals used in drug development. We propose that the same conceptual regulatory framework will be appropriate to assess readiness of new technologies that may eventually replace whole animal models.

KW - Drug development tools

KW - Regulatory qualification

KW - Safety biomarkers

UR - http://www.scopus.com/inward/record.url?scp=85014495525&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85014495525&partnerID=8YFLogxK

U2 - 10.1093/ilar/ilw032

DO - 10.1093/ilar/ilw032

M3 - Article

VL - 57

SP - 221

EP - 225

JO - ILAR Journal

JF - ILAR Journal

SN - 1084-2020

IS - 2

ER -